Liraglutide suppresses atrial electrophysiological changes

Nakamura, Hironori; Niwano, Shinichi; Niwano, Hiroe; Fukaya, Hidehira; Murakami, Masami; Kishihara, Jun; Satoh, Akira; Yoshizawa, Tomoharu; Ishizue, Naruya; Igarashi, Tazuru; Fujiishi, Tamami; Ako, Junya

doi:10.1007/s00380-018-01327-4

Cited by 20 publications

(13 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, GLP-1 RAs decrease the chance of developing cardiovascular disease and kidney damage in subjects with T2DM [187]. In parallel, GLP-1 receptor agonists are able to reduce the epicardial adipose tissue and produce beneficial electrophysiological modifications in the atrium [188].…”

Section: Newer Antihyperglycemic Agentsmentioning

confidence: 99%

Non-Alcoholic Fatty Liver Disease and Cardiovascular Comorbidities: Pathophysiological Links, Diagnosis, and Therapeutic Management

et al. 2021

View full text Add to dashboard Cite

Non-alcoholic fatty liver disease (NAFLD) has a growing prevalence in recent years. Its association with cardiovascular disease has been intensively studied, and certain correlations have been identified. The connection between these two entities has lately aroused interest regarding therapeutic management. In order to find the best therapeutic options, a detailed understanding of the pathophysiology that links (NAFLD) to cardiovascular comorbidities is needed. This review focuses on the pathogenic mechanisms that are behind these two diseases and on the therapeutic management available at this time.

show abstract

Section: Newer Antihyperglycemic Agentsmentioning

confidence: 99%

Non-Alcoholic Fatty Liver Disease and Cardiovascular Comorbidities: Pathophysiological Links, Diagnosis, and Therapeutic Management

et al. 2021

View full text Add to dashboard Cite

show abstract

“… 65 In nondiabetic tachypaced dogs, liraglutide prevented pacing-induced atrial electrical remodeling, suppressing AF susceptibility and changes in conduction velocity compared to placebo-treated controls. 66 In a study of tachypaced-induced HF in rabbits, the DPP-4 inhibitor alogliptin was found to prevent atrial fibrosis. 67 These studies in nondiabetic animals suggest that enhancing GLP-1 signaling pathways may be cardioprotective regardless of diabetic state.…”

Section: Introductionmentioning

confidence: 99%

Atrial remodeling and atrial fibrillation in acquired forms of cardiovascular disease

et al. 2020

View full text Add to dashboard Cite

Atrial fibrillation (AF) is prevalent in common conditions and acquired forms of heart disease, including diabetes mellitus (DM), hypertension, cardiac hypertrophy, and heart failure. AF is also prevalent in aging. Although acquired heart disease is common in aging individuals, age is also an independent risk factor for AF. Importantly, not all individuals age at the same rate. Rather, individuals of the same chronological age can vary in health status from fit to frail. Frailty can be quantified using a frailty index, which can be used to assess heterogeneity in individuals of the same chronological age. AF is thought to occur in association with electrical remodeling due to changes in ion channel expression or function as well as structural remodeling due to fibrosis, myocyte hypertrophy, or adiposity. These forms of remodeling can lead to triggered activity and electrical re-entry, which are fundamental mechanisms of AF initiation and maintenance. Nevertheless, the underlying determinants of electrical and structural remodeling are distinct in different conditions and disease states. In this focused review, we consider the factors leading to atrial electrical and structural remodeling in human patients and animal models of acquired cardiovascular disease or associated risk factors. Our goal is to identify similarities and differences in the cellular and molecular bases for atrial electrical and structural remodeling in conditions including DM, hypertension, hypertrophy, heart failure, aging, and frailty.

show abstract

“…In an ischemia-reperfusion model, the DPP4i alogliptin (3 mg.kg −1 ), suppressed apoptosis pathways in heart extracts ( Ihara et al., 2015 ). In a model of rapid atrial pacing, liraglutide treatment (150 µg.kg −1 ) was able to decrease the refractory period and lead to increased conduction velocity after 2 or 3 weeks ( Nakamura et al., 2019 ). Pretreatment with GLP-1 (7–36) amide (2.5 pmol.kg −1 .min −1 ) in a model of dilated cardiomyopathy decreased FFA levels and improved cardiac insulin resistance.…”

Section: Glp-1 Pharmacologymentioning

confidence: 99%

Physiological and pharmacological actions of glucagon like peptide-1 (GLP-1) in domestic animals

Model

Rocha

Fagundes

et al. 2022

Veterinary and Animal Science

View full text Add to dashboard Cite

Liraglutide suppresses atrial electrophysiological changes

Cited by 20 publications

References 18 publications

Non-Alcoholic Fatty Liver Disease and Cardiovascular Comorbidities: Pathophysiological Links, Diagnosis, and Therapeutic Management

Non-Alcoholic Fatty Liver Disease and Cardiovascular Comorbidities: Pathophysiological Links, Diagnosis, and Therapeutic Management

Atrial remodeling and atrial fibrillation in acquired forms of cardiovascular disease

Physiological and pharmacological actions of glucagon like peptide-1 (GLP-1) in domestic animals

Contact Info

Product

Resources

About